{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:22Z","timestamp":1786982722003,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00755-5","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:42:00Z","timestamp":1746283320000},"page":"1129-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Stiripentol Beyond Dravet Syndrome: A Retrospective Medical Record Review of Patients with Drug-Resistant Epilepsies"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-2901","authenticated-orcid":false,"given":"V\u00edctor","family":"Soto-Insuga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0247-9187","authenticated-orcid":false,"given":"Elena","family":"Gonz\u00e1lez-Alguacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-3252","authenticated-orcid":false,"given":"Mar\u00eda","family":"Ballar\u00e0-Petitb\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6394-6206","authenticated-orcid":false,"given":"Nuria","family":"Lamagrande-Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-4123","authenticated-orcid":false,"given":"Anna","family":"Duat-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ben\u00edtez-Provedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4757-9323","authenticated-orcid":false,"given":"Elena","family":"Cardenal-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-3287","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Garc\u00eda-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","volume":"56","author":"JL Fisher","year":"2009","unstructured":"Fisher JL. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190\u20137. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.06.004.","journal-title":"Neuropharmacology"},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","volume":"31","author":"KC Nickels","year":"2017","unstructured":"Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017;31:405\u201316. https:\/\/doi.org\/10.1007\/s40263-017-0432-1.","journal-title":"CNS Drugs"},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14737175.2023.2195550","volume":"23","author":"A Vasquez","year":"2023","unstructured":"Vasquez A, Wirrell EC, Youssef PE. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam. Expert Rev Neurother. 2023;23:297\u2013309. https:\/\/doi.org\/10.1080\/14737175.2023.2195550.","journal-title":"Expert Rev Neurother"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/epi.17201","volume":"63","author":"V Riban","year":"2022","unstructured":"Riban V, Heulard I, Reversat L, Si Hocine H, Verleye M. Stiripentol inhibits spike-and-wave discharges in animal models of absence seizures: a new mechanism of action involving T-type calcium channels. Epilepsia. 2022;63:1200\u201310. https:\/\/doi.org\/10.1111\/epi.17201.","journal-title":"Epilepsia"},{"key":"755_CR5","unstructured":"European Medicines Agency. Diacomit (stiripentol): EPAR product information. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/diacomit-epar-product-information_en.pdf. Accessed 6 Mar 2024."},{"key":"755_CR6","unstructured":"US Food and Drug Administration. Diacomit (stiripentol): prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206709s003,207223s003lbl.pdf. Accessed 6 Mar 2024."},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yebeh.2014.03.014","volume":"34","author":"A Strzelczyk","year":"2014","unstructured":"Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86\u201391. https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.014.","journal-title":"Epilepsy Behav"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/epi4.12281","volume":"4","author":"L Ouss","year":"2019","unstructured":"Ouss L, Leunen D, Laschet J, et al. Autism spectrum disorder and cognitive profile in children with Dravet syndrome: delineation of a specific phenotype. Epilepsia Open. 2019;4:40\u201353. https:\/\/doi.org\/10.1002\/epi4.12281.","journal-title":"Epilepsia Open"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(00)03157-3.","journal-title":"Lancet"},{"key":"755_CR10","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1111\/j.1528-1167.2002.tb06320.x","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial [ECE abstract P496]. Epilepsia. 2002;43:S155. https:\/\/doi.org\/10.1111\/j.1528-1167.2002.tb06320.x.","journal-title":"Epilepsia"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40120-024-00623-8","volume":"13","author":"R Guerrini","year":"2024","unstructured":"Guerrini R, Chancharme L, Serraz B, Chiron C. Additional results from two randomized, placebo-controlled trials of stiripentol in Dravet syndrome highlight a rapid antiseizure efficacy with longer seizure-free periods. Neurol Ther. 2024;13:869\u201384. https:\/\/doi.org\/10.1007\/s40120-024-00623-8.","journal-title":"Neurol Ther"},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ane.12611","volume":"135","author":"S Balestrini","year":"2017","unstructured":"Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135:73\u20139. https:\/\/doi.org\/10.1111\/ane.12611.","journal-title":"Acta Neurol Scand"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40801-022-00305-7","volume":"9","author":"S Balestrini","year":"2022","unstructured":"Balestrini S, Doccini V, Boncristiano A, et al. Efficacy and safety of long-term treatment with stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients. Drugs Real World Outcomes. 2022;9:451\u201361. https:\/\/doi.org\/10.1007\/s40801-022-00305-7.","journal-title":"Drugs Real World Outcomes"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","volume":"113","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Ohtsuka Y, Group STPS. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90\u20137. https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.012.","journal-title":"Epilepsy Res"},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","volume":"50","author":"Y Inoue","year":"2009","unstructured":"Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50:2362\u20138. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02179.x.","journal-title":"Epilepsia"},{"key":"755_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/epi.14536","volume":"59","author":"C Chiron","year":"2018","unstructured":"Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59:1705\u201317. https:\/\/doi.org\/10.1111\/epi.14536.","journal-title":"Epilepsia"},{"key":"755_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dmcn.15638","volume":"65","author":"C Chiron","year":"2023","unstructured":"Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023;65:1607\u201316. https:\/\/doi.org\/10.1111\/dmcn.15638.","journal-title":"Dev Med Child Neurol"},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/epi.12303","volume":"54","author":"EC Wirrell","year":"2013","unstructured":"Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective US study. Epilepsia. 2013;54:1595\u2013604. https:\/\/doi.org\/10.1111\/epi.12303.","journal-title":"Epilepsia"},{"key":"755_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.13036","author":"N Specchio","year":"2024","unstructured":"Specchio N, Auvin S, Strzelczyk A, et al. Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: a systematic review. Epilepsia Open. 2024. https:\/\/doi.org\/10.1002\/epi4.13036.","journal-title":"Epilepsia Open"},{"key":"755_CR20","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618\u201326. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb02048.x.","journal-title":"Epilepsia"},{"key":"755_CR21","first-page":"165","volume":"144","author":"P Loiseau","year":"1988","unstructured":"Loiseau P, Strube E, Tor J, Levy RH, Dodrill C. Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results [in French]. Rev Neurol (Paris). 1988;144:165\u201372.","journal-title":"Rev Neurol (Paris)."},{"key":"755_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00002826-198904000-00006","volume":"12","author":"O Rascol","year":"1989","unstructured":"Rascol O, Squalli A, Montastruc JL, et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clin Neuropharmacol. 1989;12:119\u201323. https:\/\/doi.org\/10.1097\/00002826-198904000-00006.","journal-title":"Clin Neuropharmacol"},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/08830738060210062101","volume":"21","author":"C Chiron","year":"2006","unstructured":"Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496\u2013502. https:\/\/doi.org\/10.1177\/08830738060210062101.","journal-title":"J Child Neurol"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","volume":"34","author":"JR Farwell","year":"1993","unstructured":"Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993;34:305\u201311. https:\/\/doi.org\/10.1111\/j.1528-1157.1993.tb02416.x.","journal-title":"Epilepsia"},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.braindev.2018.05.020","volume":"40","author":"A Alhakeem","year":"2018","unstructured":"Alhakeem A, Alshibani F, Tabarki B. Extending the use of stiripentol to SLC13A5-related epileptic encephalopathy. Brain Dev. 2018;40:827\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2018.05.020.","journal-title":"Brain Dev"},{"key":"755_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pediatrneurol.2022.11.017","volume":"139","author":"G Aungaroon","year":"2023","unstructured":"Aungaroon G, Mehta A, Horn PS, Franz DN. Stiripentol for drug-resistant epilepsy treatment in tuberous sclerosis complex. Pediatr Neurol. 2023;139:86\u201392. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.11.017.","journal-title":"Pediatr Neurol"},{"key":"755_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.seizure.2021.04.012","volume":"88","author":"E Freri","year":"2021","unstructured":"Freri E, Castellotti B, Canafoglia L, et al. Severe epilepsy in CNTNAP2-related Pitt-Hopkins-like syndrome successfully treated with stiripentol. Seizure. 2021;88:143\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2021.04.012.","journal-title":"Seizure"},{"key":"755_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/epi4.12847","volume":"9","author":"A Gil-Nagel","year":"2024","unstructured":"Gil-Nagel A, Aledo-Serrano A, Beltran-Corbellini A, et al. Efficacy and tolerability of add-on stiripentol in real-world clinical practice: an observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies. Epilepsia Open. 2024;9:164\u201375. https:\/\/doi.org\/10.1002\/epi4.12847.","journal-title":"Epilepsia Open"},{"key":"755_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.seizure.2021.03.019","volume":"88","author":"L Habermehl","year":"2021","unstructured":"Habermehl L, Mross PM, Krause K, et al. Stiripentol in the treatment of adults with focal epilepsy\u2014a retrospective analysis. Seizure. 2021;88:7\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2021.03.019.","journal-title":"Seizure"},{"key":"755_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.braindev.2012.03.016","volume":"35","author":"D Merdariu","year":"2013","unstructured":"Merdariu D, Delanoe C, Mahfoufi N, Bellavoine V, Auvin S. Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam. Brain Dev. 2013;35:177\u201380. https:\/\/doi.org\/10.1016\/j.braindev.2012.03.016.","journal-title":"Brain Dev"},{"key":"755_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ane.12403","volume":"132","author":"A Strzelczyk","year":"2015","unstructured":"Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132:435\u20139. https:\/\/doi.org\/10.1111\/ane.12403.","journal-title":"Acta Neurol Scand"},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejpn.2014.11.008","volume":"19","author":"M Trivisano","year":"2015","unstructured":"Trivisano M, Specchio N, Vigevano F. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. Eur J Paediatr Neurol. 2015;19:248\u201350. https:\/\/doi.org\/10.1016\/j.ejpn.2014.11.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"755_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2016.12.020","volume":"373","author":"Y Uchida","year":"2017","unstructured":"Uchida Y, Kato D, Toyoda T, et al. Combination of ketogenic diet and stiripentol for super-refractory status epilepticus: a case report. J Neurol Sci. 2017;373:35\u20137. https:\/\/doi.org\/10.1016\/j.jns.2016.12.020.","journal-title":"J Neurol Sci"},{"key":"755_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ane.12888","volume":"137","author":"Y Uchida","year":"2018","unstructured":"Uchida Y, Terada K, Madokoro Y, et al. Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity. Acta Neurol Scand. 2018;137:432\u20137. https:\/\/doi.org\/10.1111\/ane.12888.","journal-title":"Acta Neurol Scand"},{"key":"755_CR35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1528-1157.1995.tb00961.x","volume":"36","author":"G Coppola","year":"1995","unstructured":"Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia. 1995;36:1017\u201324. https:\/\/doi.org\/10.1111\/j.1528-1157.1995.tb00961.x.","journal-title":"Epilepsia"},{"key":"755_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1684\/epd.2011.0402","volume":"13","author":"M Djuric","year":"2011","unstructured":"Djuric M, Kravljanac R, Kovacevic G, Martic J. The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy. Epileptic Disord. 2011;13:22\u20136. https:\/\/doi.org\/10.1684\/epd.2011.0402.","journal-title":"Epileptic Disord"},{"key":"755_CR37","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63:1398\u2013442. https:\/\/doi.org\/10.1111\/epi.17241.","journal-title":"Epilepsia"},{"key":"755_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"755_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512\u201321. https:\/\/doi.org\/10.1111\/epi.13709.","journal-title":"Epilepsia"},{"key":"755_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515\u201323. https:\/\/doi.org\/10.1111\/epi.13121.","journal-title":"Epilepsia"},{"key":"755_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106535","volume":"170","author":"M Yamada","year":"2021","unstructured":"Yamada M, Suzuki K, Matsui D, Inoue Y, Ohtsuka Y. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan. Epilepsy Res. 2021;170: 106535. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106535.","journal-title":"Epilepsy Res"},{"key":"755_CR42","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/epi.16363","volume":"60","author":"A Rosati","year":"2019","unstructured":"Rosati A, Boncristiano A, Doccini V, et al. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: a single center prospective observational study. Epilepsia. 2019;60:2255\u201362. https:\/\/doi.org\/10.1111\/epi.16363.","journal-title":"Epilepsia"},{"key":"755_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109553","volume":"150","author":"C Ballesteros-Sayas","year":"2024","unstructured":"Ballesteros-Sayas C, Munoz-Montero A, Giorgi S, et al. Non-pharmacological therapeutic needs in people with Dravet syndrome. Epilepsy Behav. 2024;150: 109553. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109553.","journal-title":"Epilepsy Behav"},{"key":"755_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","volume":"41","author":"A Bacq","year":"2024","unstructured":"Bacq A, Depaulis A, Castagne V, et al. An update on stiripentol mechanisms of action: a narrative review. Adv Ther. 2024;41:1351\u201371. https:\/\/doi.org\/10.1007\/s12325-024-02813-0.","journal-title":"Adv Ther"},{"key":"755_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00677-8","author":"JJ Garcia-Penas","year":"2024","unstructured":"Garcia-Penas JJ, Calvo-Medina R, Garcia-Ron A, et al. Use of stiripentol in patients with Dravet syndrome: common practice among experts in Spain. Neurol Ther. 2024. https:\/\/doi.org\/10.1007\/s40120-024-00677-8.","journal-title":"Neurol Ther"},{"key":"755_CR46","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/epi4.12923","volume":"9","author":"R Guerrini","year":"2024","unstructured":"Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: a network meta-analysis. Epilepsia Open. 2024;9:689\u2013703. https:\/\/doi.org\/10.1002\/epi4.12923.","journal-title":"Epilepsia Open"},{"key":"755_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3\u201323. https:\/\/doi.org\/10.1007\/s12028-012-9695-z.","journal-title":"Neurocrit Care"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00755-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:57:56Z","timestamp":1747648676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00755-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00755-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V\u00edctor Soto-Insuga, Elena Gonz\u00e1lez-Alguacil, Anna Duat-Rodr\u00edguez and Juan Jos\u00e9 Garc\u00eda-Pe\u00f1as received fees for Advisory Boards, travel and registration for scientific meetings from UCB, Eisai, Nutricia, Biocodex, GW-Jazz Pharmaceuticals and Takeda. Mar\u00eda Ballar\u00e0-Petitb\u00f2, Cristina Ben\u00edtez-Provedo and Nuria Lamagrande-Casanova have no conflicts of interest. Elena Cardenal-Mu\u00f1oz is a full-time employee of Biocodex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki code of ethics, and satisfied the conditions of standard clinical practice in our hospital, as well as the principles of Good Clinical Practice. Ethics committee approval was obtained from the Ni\u00f1o Jes\u00fas University Children\u2019s Hospital in Madrid (number R-0025\/25). Written informed consent was obtained for the use of medical records in research from all parents or legal guardians of patients treated at the Neurology Service of the Ni\u00f1o Jes\u00fas University Children\u2019s Hospital in Madrid, Spain. Patient data were de-identified before being processed. The study adhered to the STROBE (Strengthening the Reporting of OBservational studies in Epidemiology) guidelines [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}